Full-Time

Group Leader

Functional Genomics

Confirmed live in the last 24 hours

NewLimit

NewLimit

11-50 employees

Develops medicines for epigenetic reprogramming

Biotechnology
Healthcare

Senior, Expert

San Bruno, CA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech

You match the following NewLimit's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. in molecular biology, cell biology, or a related field or equivalent industry experience (5+ years)
  • Experience leading a cross-functional team and managing direct reports
  • Experience with functional genomics approaches for arrayed or pooled screening (e.g. one of: CRISPR-Cas pooled fitness screens, gene expression perturbation profiling, CROP/Perturb-seq, or similar methods)
  • Experience with *in vitro* and *in vivo* transgenic delivery methods for mammalian cells (at least one of: lentivirus, AAV, AdV, transposition systems, CRISPR-Cas targeted editing, lipid nanoparticles, or similar)
Responsibilities
  • Lead & recruit a team of Scientists and Research Associates
  • Develop new functional genomics technology & execute production scale reprogramming screens in collaboration with our Single Cell Technology & Predictive Modeling teams
  • Contribute to laboratory implementations and training at the bench — [**Everyone Executes**](https://www.newlimit.com/about) at NewLimit
  • Develop methods for the construction, delivery, and control of partial reprogramming payloads in primary mammalian cells of diverse cell types
  • Contribute to company-wide decision making on indication selection, program prioritization, and resource allocation
Desired Qualifications
  • Therapeutics discovery & development experience
  • Experience with epigenetic reprogramming methods using transcription factors for cell fate engineering or CRISPR-Cas tools for targeted epigenetic editing
  • Experience working with primary cells and tissue samples
  • Experience with single cell genomics methods
  • Programming ability in one of: Python, R, Rust

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This process involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company utilizes advanced technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify aging markers and create interventions that reverse these changes. NewLimit serves the healthcare market, targeting patients with age-related diseases and collaborating with pharmaceutical companies and healthcare providers. Its goal is to create a new class of medicines that significantly increase the duration of healthy living.

Company Size

11-50

Company Stage

Series A

Total Funding

$38.9M

Headquarters

South San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in epigenetic reprogramming boosts NewLimit's market potential.
  • Machine learning aids in identifying novel drug candidates for age-related diseases.
  • FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

What critics are saying

  • Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.
  • Ethical concerns and regulatory scrutiny may delay product approvals.
  • Competition from similar biotech firms could impact NewLimit's market share.

What makes NewLimit unique

  • NewLimit focuses on epigenetic reprogramming to extend human healthspan.
  • The company uses single-cell genomics and machine learning for drug discovery.
  • NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
NewLimit
May 17th, 2023
NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors

NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging

TechCrunch
May 16th, 2023
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $40M to extend life

NewLimit aims to increase the number of healthy years each person lives by epigenetically reprogramming cells.

Fortune
May 16th, 2023
Coinbase's Armstrong gets $40M for anti-aging startup | Fortune Crypto

NewLimit, a startup that aspires to reverse aging by manipulating cells, announced on Tuesday that it’s raised $40 million in a Series A round from Kleiner Perkins and other venture firms, and from prominent individuals like former Google CEO Eric Schmidt and Y Combinator CEO Garry Tan.